

Poteligeo® (mogamulizumab-kpkc) – New orphan drug approval

- On August 8, 2018, the <u>FDA announced</u> the approval of <u>Kyowa Kirin's Poteligeo (mogamulizumab-kpkc)</u> for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
- MF and SS are rare, hard-to-treat forms of non-Hodgkin lymphoma (NHL), a cancer that begins in lymphocytes.
 - MF accounts for about half of all lymphomas arising from the skin. It causes itchy red rashes and skin lesions and can spread to other parts of the body.
 - SS is a form of skin lymphoma that affects the blood and lymph nodes.
- Poteligeo is a monoclonal antibody that binds to CC chemokine receptor type 4, which is found on some cancer cells.
- The efficacy and safety of Poteligeo were based on an open-label study in 372 adult patients with MF or SS after at least one prior systemic therapy. Patients were given either Poteligeo or <u>Zolinza</u> (<u>vorinostat</u>). The primary endpoint was progression-free survival (PFS).
 - The median PFS was 7.6 months with Poteligeo vs. 3.1 months with vorinostat (HR = 0.53 [95% CI: 0.41, 0.69, p < 0.001]).
 - In addition, the overall response rate was 52% with Poteligeo vs. 9% with vorinostat (p < 0.001).
- Warnings and precautions of Poteligeo include dermatologic toxicity, infusion reactions, infections, autoimmune complications, and complications of allogeneic hematopoietic stem cell transplantation after Poteligeo.
- The most common adverse reactions (≥ 20%) with Poteligeo use were rash, infusion related reactions, fatigue, diarrhea, musculoskeletal pain, and upper respiratory tract infection.
- The recommended dose of Poteligeo is 1 mg/kg administered as an intravenous infusion on days 1, 8, 15, and 22 of the first 28-day cycle, then on days 1 and 15 of each subsequent 28-day cycle until disease progression or unacceptable toxicity.
 - Premedication should be administered with <u>diphenhydramine</u> and <u>acetaminophen</u> for the first Poteligeo infusion.
- Kyowa Kirin plans to launch Poteligeo in the fourth quarter of 2018. Poteligeo will be available as a 20 mg/5 mL solution in a single-dose vial.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.